Cheryl R. Blanchard is Director at Anika Therapeutics, Inc. (ANIK). They have made 1 open-market trade across 1 company since 2007, most recently 2026-03-15.
CIK 0001326530
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $414K since 2022, never a sale. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ANIK | BUY | 2022-03-11 | 2022-03-14 | $25.57 | $414K | +5.1% | -3.4% | -19.2% |
| ZMH | SELL · 10b5-1 | 2012-01-10 | 2012-01-11 | $55.00 | $660K | N/A | N/A | N/A |
| ZMH | SELL · 10b5-1 | 2011-02-18 | 2011-02-22 | $65.00 | $260K | N/A | N/A | N/A |
| ZMH | SELL · 10b5-1 | 2007-02-20 | 2007-02-20 | $86.00 | $516K | N/A | N/A | N/A |
| ZMH | SELL · 10b5-1 | 2007-01-30 | 2007-01-31 | $83.83 | $1.2M | N/A | N/A | N/A |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.